Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Mate tea (Ilex paraguariensis) improves glycemic and lipid profiles of type 2 diabetes and pre-diabetes individuals: a pilot study.

Klein GA, Stefanuto A, Boaventura BC, de Morais EC, Cavalcante Lda S, de Andrade F, Wazlawik E, Di Pietro PF, Maraschin M, da Silva EL.

J Am Coll Nutr. 2011 Oct;30(5):320-32.

PMID:
22081618
2.

Consumption of yerba mate ( Ilex paraguariensis ) improves serum lipid parameters in healthy dyslipidemic subjects and provides an additional LDL-cholesterol reduction in individuals on statin therapy.

de Morais EC, Stefanuto A, Klein GA, Boaventura BC, de Andrade F, Wazlawik E, Di Pietro PF, Maraschin M, da Silva EL.

J Agric Food Chem. 2009 Sep 23;57(18):8316-24. doi: 10.1021/jf901660g.

PMID:
19694438
3.

Association of mate tea (Ilex paraguariensis) intake and dietary intervention and effects on oxidative stress biomarkers of dyslipidemic subjects.

Boaventura BC, Di Pietro PF, Stefanuto A, Klein GA, de Morais EC, de Andrade F, Wazlawik E, da Silva EL.

Nutrition. 2012 Jun;28(6):657-64. doi: 10.1016/j.nut.2011.10.017.

PMID:
22578980
5.

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.

Bays HE, Goldberg RB, Truitt KE, Jones MR.

Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975.

PMID:
18852398
6.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
8.

The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus.

Ko SH, Song KH, Ahn YB, Yoo SJ, Son HS, Yoon KH, Cha BY, Lee KW, Son HY, Kang SK.

Metabolism. 2003 Jun;52(6):731-4.

PMID:
12800099
9.

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group..

Coron Artery Dis. 2001 Aug;12(5):413-23.

PMID:
11491207
11.

The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein.

Wolever TM, Gibbs AL, Mehling C, Chiasson JL, Connelly PW, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA.

Am J Clin Nutr. 2008 Jan;87(1):114-25.

12.

Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone.

Kutoh E.

Postgrad Med. 2011 Jan;123(1):45-52. doi: 10.3810/pgm.2011.01.2244.

PMID:
21293083
13.
15.

Yerba mate (Ilex paraguariensis) improves microcirculation of volunteers with high blood viscosity: a randomized, double-blind, placebo-controlled trial.

Yu S, Yue Sw, Liu Z, Zhang T, Xiang N, Fu H.

Exp Gerontol. 2015 Feb;62:14-22. doi: 10.1016/j.exger.2014.12.016. Epub 2015 Jan 3.

PMID:
25562195
16.

Antiobesity effects of yerba maté extract (Ilex paraguariensis) in high-fat diet-induced obese mice.

Arçari DP, Bartchewsky W, dos Santos TW, Oliveira KA, Funck A, Pedrazzoli J, de Souza MF, Saad MJ, Bastos DH, Gambero A, Carvalho Pde O, Ribeiro ML.

Obesity (Silver Spring). 2009 Dec;17(12):2127-33. doi: 10.1038/oby.2009.158. Epub 2009 May 14.

17.
18.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
20.

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.

Clin Ther. 2003 Apr;25(4):1074-95.

PMID:
12809958

Supplemental Content

Support Center